Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
Ethinyl estradiol 5 microgram and norethindrone acetate 1 mg oral tablet |
Count of base of active ingredient |
False |
deux |
Inferred relationship |
Some |
|
Diphenhydramine 25 mg and ibuprofen 200 mg oral capsule |
Count of base of active ingredient |
False |
deux |
Inferred relationship |
Some |
|
Product containing precisely hydrochlorothiazide 12.5 milligram and metoprolol tartrate 50 milligram/1 each conventional release oral tablet (clinical drug) |
Count of base of active ingredient |
False |
deux |
Inferred relationship |
Some |
|
Ethinyl estradiol 20 microgram and norethindrone acetate 1 mg oral tablet |
Count of base of active ingredient |
False |
deux |
Inferred relationship |
Some |
|
Product containing precisely levothyroxine sodium 100 microgram and liothyronine sodium 25 microgram/1 each conventional release oral tablet (clinical drug) |
Count of base of active ingredient |
False |
deux |
Inferred relationship |
Some |
|
Product containing precisely ethinylestradiol 30 microgram and norethisterone acetate 1.5 milligram/1 each conventional release oral tablet (clinical drug) |
Count of base of active ingredient |
False |
deux |
Inferred relationship |
Some |
|
Hydrochlorothiazide 15 mg and methyldopa 250 mg oral tablet |
Count of base of active ingredient |
False |
deux |
Inferred relationship |
Some |
|
Homatropine methylbromide 1.5 mg and hydrocodone bitartrate 5 mg oral tablet |
Count of base of active ingredient |
False |
deux |
Inferred relationship |
Some |
|
Acetaminophen 500 mg and hydrocodone bitartrate 2.5 mg oral tablet |
Count of base of active ingredient |
False |
deux |
Inferred relationship |
Some |
|
Product containing precisely fluoxetine hydrochloride 25 milligram and olanzapine 6 milligram/1 each conventional release oral capsule (clinical drug) |
Count of base of active ingredient |
False |
deux |
Inferred relationship |
Some |
|
Drospirenone 2 mg and estradiol 1 mg oral tablet |
Count of base of active ingredient |
False |
deux |
Inferred relationship |
Some |
|
Product containing precisely omeprazole 40 milligram and sodium bicarbonate 1.1 gram/1 each conventional release oral capsule (clinical drug) |
Count of base of active ingredient |
False |
deux |
Inferred relationship |
Some |
|
Product containing precisely hydrochlorothiazide 12.5 milligram and lisinopril 10 milligram/1 each conventional release oral tablet (clinical drug) |
Count of base of active ingredient |
False |
deux |
Inferred relationship |
Some |
|
Pyrimethamine 25 mg and sulfadoxine 500 mg oral tablet |
Count of base of active ingredient |
False |
deux |
Inferred relationship |
Some |
|
Acetaminophen 400 mg and hydrocodone bitartrate 5 mg oral tablet |
Count of base of active ingredient |
False |
deux |
Inferred relationship |
Some |
|
Product containing precisely levothyroxine sodium 25 microgram and liothyronine sodium 6.25 microgram/1 each conventional release oral tablet (clinical drug) |
Count of base of active ingredient |
False |
deux |
Inferred relationship |
Some |
|
Glipizide 5 mg and metformin hydrochloride 500 mg oral tablet |
Count of base of active ingredient |
False |
deux |
Inferred relationship |
Some |
|
Ibuprofen 400 mg and oxycodone 5 mg oral tablet |
Count of base of active ingredient |
False |
deux |
Inferred relationship |
Some |
|
Product containing precisely hydralazine hydrochloride 100 milligram and hydrochlorothiazide 50 milligram/1 each conventional release oral capsule (clinical drug) |
Count of base of active ingredient |
False |
deux |
Inferred relationship |
Some |
|
Eprosartan mesylate 600 mg and hydrochlorothiazide 25 mg oral tablet |
Count of base of active ingredient |
False |
deux |
Inferred relationship |
Some |
|
Levothyroxine sodium 50 microgram and liothyronine sodium 12.5 microgram oral tablet |
Count of base of active ingredient |
False |
deux |
Inferred relationship |
Some |
|
Drospirenone 500 microgram and estradiol 1 mg oral tablet |
Count of base of active ingredient |
False |
deux |
Inferred relationship |
Some |
|
Product containing precisely fluoxetine hydrochloride 50 milligram and olanzapine 12 milligram/1 each conventional release oral capsule (clinical drug) |
Count of base of active ingredient |
False |
deux |
Inferred relationship |
Some |
|
Product containing precisely hydralazine hydrochloride 25 milligram and hydrochlorothiazide 25 milligram/1 each conventional release oral capsule (clinical drug) |
Count of base of active ingredient |
False |
deux |
Inferred relationship |
Some |
|
Eprosartan mesylate 600 mg and hydrochlorothiazide 12.5 mg oral tablet |
Count of base of active ingredient |
False |
deux |
Inferred relationship |
Some |
|
Product containing precisely levothyroxine sodium 12.5 microgram and liothyronine sodium 3.1 microgram/1 each conventional release oral tablet (clinical drug) |
Count of base of active ingredient |
False |
deux |
Inferred relationship |
Some |
|
Product containing precisely hydralazine hydrochloride 50 milligram and hydrochlorothiazide 50 milligram/1 each conventional release oral capsule (clinical drug) |
Count of base of active ingredient |
False |
deux |
Inferred relationship |
Some |
|
Product containing precisely furosemide 40 milligram and triamterene 50 milligram/1 each conventional release oral tablet (clinical drug) |
Count of base of active ingredient |
False |
deux |
Inferred relationship |
Some |
|
Product containing precisely naproxen sodium 500 milligram and sumatriptan succinate 85 milligram/1 each conventional release oral tablet (clinical drug) |
Count of base of active ingredient |
False |
deux |
Inferred relationship |
Some |
|
Levothyroxine sodium 150 microgram and liothyronine sodium 37.5 microgram oral tablet |
Count of base of active ingredient |
False |
deux |
Inferred relationship |
Some |
|
Furosemide 20 mg and spironolactone 50 mg oral capsule |
Count of base of active ingredient |
False |
deux |
Inferred relationship |
Some |
|
Ethinyl estradiol 20 microgram and levonorgestrel 90 microgram oral tablet |
Count of base of active ingredient |
False |
deux |
Inferred relationship |
Some |
|
Product containing precisely emtricitabine 200 milligram and tenofovir disoproxil fumarate 136 milligram/1 each conventional release oral tablet (clinical drug) |
Count of base of active ingredient |
False |
deux |
Inferred relationship |
Some |
|
Acetaminophen 660 mg and hydrocodone bitartrate 10 mg oral tablet |
Count of base of active ingredient |
False |
deux |
Inferred relationship |
Some |
|
Lopinavir 133.3 mg and ritonavir 33.3 mg oral capsule |
Count of base of active ingredient |
False |
deux |
Inferred relationship |
Some |
|
Loratadine 10 mg and pseudoephedrine sulfate 240 mg oral tablet |
Count of base of active ingredient |
False |
deux |
Inferred relationship |
Some |
|
Product containing precisely ferrous fumarate 305 milligram and folic acid 350 microgram/1 each conventional release oral capsule (clinical drug) |
Count of base of active ingredient |
False |
deux |
Inferred relationship |
Some |
|
Product containing precisely fluoxetine hydrochloride 50 milligram and olanzapine 6 milligram/1 each conventional release oral capsule (clinical drug) |
Count of base of active ingredient |
False |
deux |
Inferred relationship |
Some |
|
Product containing precisely ferrous fumarate 322 milligram and folic acid 350 microgram/1 each conventional release oral tablet (clinical drug) |
Count of base of active ingredient |
False |
deux |
Inferred relationship |
Some |
|
Hydrochlorothiazide 25 mg and labetalol hydrochloride 300 mg oral tablet |
Count of base of active ingredient |
False |
deux |
Inferred relationship |
Some |
|
Product containing precisely glimepiride 1 milligram and rosiglitazone maleate 4 milligram/1 each conventional release oral tablet (clinical drug) |
Count of base of active ingredient |
False |
deux |
Inferred relationship |
Some |
|
Product containing precisely pethidine hydrochloride 50 milligram and promethazine hydrochloride 25 milligram/1 each conventional release oral capsule (clinical drug) |
Count of base of active ingredient |
False |
deux |
Inferred relationship |
Some |
|
Product containing precisely cyclophosphamide (as cyclophosphamide monohydrate) 2 gram/1 vial powder for conventional release solution for injection (clinical drug) |
Has presentation strength numerator value (attribute) |
False |
deux |
Inferred relationship |
Some |
1 |
céfoxitine 2 g, pour injection (poudre pour reconstitution) (médicament clinique) |
Has presentation strength numerator value (attribute) |
False |
deux |
Inferred relationship |
Some |
1 |
amoxicilline et clavulanate de potassium 1 mg/200 mg, fiole de poudre pour solution injectable (médicament clinique) |
Count of base of active ingredient |
False |
deux |
Inferred relationship |
Some |
|
aztréonam 2 g, fiole de poudre pour solution injectable (médicament clinique) |
Has presentation strength numerator value (attribute) |
False |
deux |
Inferred relationship |
Some |
1 |
Product containing precisely aspirin DL-lysine 900 milligram and metoclopramide hydrochloride 10 milligram/1 sachet conventional release oral powder (clinical drug) |
Count of base of active ingredient |
False |
deux |
Inferred relationship |
Some |
|
Product containing precisely benorilate 2 gram/1 sachet granules for conventional release oral suspension (clinical drug) |
Has presentation strength numerator value (attribute) |
False |
deux |
Inferred relationship |
Some |
1 |
amoxicilline et clavulanate de potassium 500 mg/100 mg, fiole de poudre pour solution injectable (médicament clinique) |
Count of base of active ingredient |
False |
deux |
Inferred relationship |
Some |
|
Deferoxamine mesylate 2 g powder for solution for injection vial |
Has presentation strength numerator value (attribute) |
False |
deux |
Inferred relationship |
Some |
1 |
ampicilline et floxacilline 250 mg/250 mg, fiole de poudre pour solution injectable (médicament clinique) |
Count of base of active ingredient |
False |
deux |
Inferred relationship |
Some |
|
ceftazidime 2 g, pour injection (poudre pour reconstitution) (médicament clinique) |
Has presentation strength numerator value (attribute) |
False |
deux |
Inferred relationship |
Some |
1 |
ceftriaxone 2 g, pour injection (poudre pour reconstitution) (médicament clinique) |
Has presentation strength numerator value (attribute) |
False |
deux |
Inferred relationship |
Some |
1 |
cefpirome 2 g, fiole de poudre pour solution injectable (médicament clinique) |
Has presentation strength numerator value (attribute) |
False |
deux |
Inferred relationship |
Some |
1 |
Ifosfamide 2 g powder for solution for injection vial |
Has presentation strength numerator value (attribute) |
False |
deux |
Inferred relationship |
Some |
1 |
pipéracilline 4 g/tazobactam 500 mg, fiole de poudre pour solution injectable (médicament clinique) |
Count of base of active ingredient |
False |
deux |
Inferred relationship |
Some |
|
quinupristine 150 mg et dalfopristine 350 mg, fiole de poudre pour perfusion |
Count of base of active ingredient |
False |
deux |
Inferred relationship |
Some |
|
Product containing precisely codeine phosphate 30 milligram and paracetamol 500 milligram/1 sachet effervescent powder for conventional release oral suspension (clinical drug) |
Count of base of active ingredient |
False |
deux |
Inferred relationship |
Some |
|
Product containing precisely codeine phosphate 60 milligram and paracetamol 1 gram/1 sachet effervescent powder for conventional release oral suspension (clinical drug) |
Count of base of active ingredient |
False |
deux |
Inferred relationship |
Some |
|
Remifentanil (as remifentanil hydrochloride) 2 mg powder for solution for injection vial |
Has presentation strength numerator value (attribute) |
False |
deux |
Inferred relationship |
Some |
1 |
Acetaminophen 500 mg and metoclopramide hydrochloride 5 mg effervescent powder for oral suspension sachet |
Count of base of active ingredient |
False |
deux |
Inferred relationship |
Some |
|
Raltitrexed 2 mg powder for solution for injection vial |
Has presentation strength numerator value (attribute) |
False |
deux |
Inferred relationship |
Some |
1 |
Cilastatin (as cilastatin sodium) 500 mg and imipenem (as imipenem monohydrate) 500 mg powder for suspension for injection vial |
Count of base of active ingredient |
False |
deux |
Inferred relationship |
Some |
|
Product containing precisely ispaghula husk 3.5 gram and mebeverine hydrochloride 135 milligram/1 sachet granules for conventional release oral suspension (clinical drug) |
Count of base of active ingredient |
False |
deux |
Inferred relationship |
Some |
|
Somatropin(rbe) 2 mg powder for solution for injection syringe |
Has presentation strength numerator value (attribute) |
False |
deux |
Inferred relationship |
Some |
1 |
ticarcilline 3 g/acide clavulanique 200 mg, fiole de poudre pour perfusion (médicament clinique) |
Count of base of active ingredient |
False |
deux |
Inferred relationship |
Some |
|
Magnesium alginate 87.5 mg and sodium alginate 225 mg powder for oral suspension sachet |
Count of base of active ingredient |
False |
deux |
Inferred relationship |
Some |
|
Galactose 2.49 g and palmitic acid 2.5 mg powder for suspension for injection vial |
Count of base of active ingredient |
False |
deux |
Inferred relationship |
Some |
|
Galactose 3.99 g and palmitic acid 4 mg powder for suspension for injection vial |
Count of base of active ingredient |
False |
deux |
Inferred relationship |
Some |
|
Mitomycin 2 mg powder for solution for injection vial |
Has presentation strength numerator value (attribute) |
False |
deux |
Inferred relationship |
Some |
1 |
pipéracilline 2 g/tazobactam 250 mg, fiole de poudre pour solution injectable (médicament clinique) |
Has presentation strength numerator value (attribute) |
False |
deux |
Inferred relationship |
Some |
2 |
pipéracilline 2 g/tazobactam 250 mg, fiole de poudre pour solution injectable (médicament clinique) |
Count of base of active ingredient |
False |
deux |
Inferred relationship |
Some |
|
Product containing precisely dantron 10 milligram/1 milliliter and docusate sodium 12 milligram/1 milliliter conventional release oral suspension (clinical drug) |
Count of base of active ingredient |
False |
deux |
Inferred relationship |
Some |
|
Dihydrocodeine tartrate 2 mg/mL oral solution |
Has concentration strength numerator value (attribute) |
False |
deux |
Inferred relationship |
Some |
1 |
Ferric ammonium citrate 16 mg/mL and folic acid 500 microgram/mL oral solution |
Count of base of active ingredient |
False |
deux |
Inferred relationship |
Some |
|
Ferric ammonium citrate 16 mg/mL and folic acid 100 microgram/mL oral solution |
Count of base of active ingredient |
False |
deux |
Inferred relationship |
Some |
|
Product containing precisely hydroxyzine hydrochloride 2 milligram/1 milliliter conventional release oral solution (clinical drug) |
Has concentration strength numerator value (attribute) |
False |
deux |
Inferred relationship |
Some |
1 |
Metaproterenol sulfate 2 mg/mL oral solution |
Has concentration strength numerator value (attribute) |
False |
deux |
Inferred relationship |
Some |
1 |
Diazepam 2 mg/mL oral suspension |
Has concentration strength numerator value (attribute) |
False |
deux |
Inferred relationship |
Some |
1 |
Product containing precisely dantron 15 milligram/1 milliliter and poloxamer 188 200 milligram/1 milliliter conventional release oral suspension (clinical drug) |
Count of base of active ingredient |
False |
deux |
Inferred relationship |
Some |
|
Product containing precisely amoxicillin (as amoxicillin trihydrate) 50 milligram/1 milliliter and clavulanic acid (as clavulanate potassium) 12.5 milligram/1 milliliter conventional release oral suspension (clinical drug) |
Count of base of active ingredient |
False |
deux |
Inferred relationship |
Some |
|
Diphenhydramine hydrochloride 2 mg/mL oral solution |
Has concentration strength numerator value (attribute) |
False |
deux |
Inferred relationship |
Some |
1 |
Product containing precisely morphine sulfate 2 milligram/1 milliliter conventional release oral solution (clinical drug) |
Has concentration strength numerator value (attribute) |
False |
deux |
Inferred relationship |
Some |
1 |
Sulfamethoxazole 80 mg/mL and trimethoprim 16 mg/mL oral suspension |
Count of base of active ingredient |
False |
deux |
Inferred relationship |
Some |
|
Product containing precisely prednisolone 2 milligram/1 milliliter conventional release oral solution (clinical drug) |
Has concentration strength numerator value (attribute) |
False |
deux |
Inferred relationship |
Some |
1 |
Product containing precisely paroxetine (as paroxetine hydrochloride) 2 milligram/1 milliliter conventional release oral suspension (clinical drug) |
Has concentration strength numerator value (attribute) |
False |
deux |
Inferred relationship |
Some |
1 |
Dried aluminium hydroxide gel 44 mg/mL and magnesium hydroxide 39 mg/mL oral suspension |
Count of base of active ingredient |
False |
deux |
Inferred relationship |
Some |
|
Product containing precisely spironolactone 2 milligram/1 milliliter conventional release oral suspension (clinical drug) |
Has concentration strength numerator value (attribute) |
False |
deux |
Inferred relationship |
Some |
1 |
Dried aluminium hydroxide gel 120 mg/mL and magnesium hydroxide 60 mg/mL oral suspension |
Count of base of active ingredient |
False |
deux |
Inferred relationship |
Some |
|
Ampicillin (as ampicillin trihydrate) 25 mg/mL and floxacillin (as floxacillin magnesium) 25 mg/mL oral suspension |
Count of base of active ingredient |
False |
deux |
Inferred relationship |
Some |
|
Product containing precisely methadone hydrochloride 2 milligram/1 milliliter conventional release oral solution (clinical drug) |
Has concentration strength numerator value (attribute) |
False |
deux |
Inferred relationship |
Some |
1 |
Pholcodine 2 mg/mL oral solution |
Has concentration strength numerator value (attribute) |
False |
deux |
Inferred relationship |
Some |
1 |
Product containing precisely periciazine 2 milligram/1 milliliter conventional release oral solution (clinical drug) |
Has concentration strength numerator value (attribute) |
False |
deux |
Inferred relationship |
Some |
1 |
Product containing precisely amoxicillin (as amoxicillin trihydrate) 25 milligram/1 milliliter and clavulanic acid (as clavulanate potassium) 6.25 milligram/1 milliliter conventional release oral suspension (clinical drug) |
Count of base of active ingredient |
False |
deux |
Inferred relationship |
Some |
|
Dicyclomine hydrochloride 2 mg/mL oral solution |
Has concentration strength numerator value (attribute) |
False |
deux |
Inferred relationship |
Some |
1 |
Product containing precisely lopinavir 80 milligram/1 milliliter and ritonavir 20 milligram/1 milliliter conventional release oral solution (clinical drug) |
Count of base of active ingredient |
False |
deux |
Inferred relationship |
Some |
|
Clorquinaldol 30 mg/g and hydrocortisone butyrate 1 mg/g cutaneous ointment |
Count of base of active ingredient |
False |
deux |
Inferred relationship |
Some |
|
Product containing precisely phenothrin 2 milligram/1 milliliter conventional release cutaneous lotion (clinical drug) |
Has concentration strength numerator value (attribute) |
False |
deux |
Inferred relationship |
Some |
1 |
Midazolam (as midazolam hydrochloride) 2 mg/mL oral solution |
Has concentration strength numerator value (attribute) |
False |
deux |
Inferred relationship |
Some |
1 |
Clorquinaldol 30 mg/g and hydrocortisone butyrate 1 mg/g cutaneous cream |
Count of base of active ingredient |
False |
deux |
Inferred relationship |
Some |
|
Product containing precisely sodium fluoride 2 milligram/1 gram conventional release oromucosal solution (clinical drug) |
Has concentration strength numerator value (attribute) |
False |
deux |
Inferred relationship |
Some |
1 |